Significant results from new brain cancer drugs as Chroma platform matures Highlights • Novel brain cancer drug candidates significantly reduce tumour growth • Important ability to cross blood-brain barrier • Promising early Chroma™ drug candidate for leukaemia Sydney, 3 September 2024: Innovative biotech company Noxopharm Limited (ASX:NOX) is pleased to announce substantial progress on its Chroma™ technology platform, with encouraging brain cancer results plus early work on leukaemia. Glioblastoma is the most frequent and lethal type of brain cancer, accounting for two-thirds of all Australian brain cancers. It remains an incurable disease with a median survival time of just 15 months after diagnosis. Today there are only a few treatment options available, and after initial treatment recurrence of the disease is almost inevitable. The global glioblastoma market was worth around US$2.9 billion in 2022 and is expected to grow at an annual rate of 8.8%.
